JPH0222229A - 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤 - Google Patents

神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤

Info

Publication number: JPH0222229A
Authority: JP; Japan
Prior art keywords: acid; tebonine; preparation; preparation according; combination preparation
Prior art date: 1988-01-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP1022466A

Other languages

English (en)

Japanese (ja)

Inventor

Peter Koeltringer

ペーター　コルトリンガー

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-01-28

Filing date

1989-01-30

Publication date

1990-01-25

1988-02-01 Priority claimed from DE19883802895 external-priority patent/DE3802895A1/de

1989-01-30 Application filed by Individual filed Critical Individual

1990-01-25 Publication of JPH0222229A publication Critical patent/JPH0222229A/ja

Status Pending legal-status Critical Current

Links

238000002360 preparation method Methods 0.000 title claims abstract description 50
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 27
201000010099 disease Diseases 0.000 title claims description 10
210000004126 nerve fiber Anatomy 0.000 title claims description 10
210000002569 neuron Anatomy 0.000 title claims description 10
230000006378 damage Effects 0.000 title description 6
208000027418 Wounds and injury Diseases 0.000 title description 5
208000014674 injury Diseases 0.000 title description 5
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 22
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims abstract description 14
MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims abstract description 14
235000008191 folinic acid Nutrition 0.000 claims abstract description 14
239000011672 folinic acid Substances 0.000 claims abstract description 14
229960001691 leucovorin Drugs 0.000 claims abstract description 14
239000002253 acid Substances 0.000 claims abstract description 13
235000019152 folic acid Nutrition 0.000 claims abstract description 12
239000011724 folic acid Substances 0.000 claims abstract description 12
235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 11
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 11
229960000304 folic acid Drugs 0.000 claims abstract description 11
-1 flavone glycoside Chemical class 0.000 claims abstract description 10
235000011201 Ginkgo Nutrition 0.000 claims abstract description 9
GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 9
239000013543 active substance Substances 0.000 claims abstract description 9
229930003944 flavone Natural products 0.000 claims abstract description 9
235000011949 flavones Nutrition 0.000 claims abstract description 9
VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 9
229930182470 glycoside Natural products 0.000 claims abstract description 8
239000000284 extract Substances 0.000 claims abstract description 6
235000019156 vitamin B Nutrition 0.000 claims abstract description 6
239000011720 vitamin B Substances 0.000 claims abstract description 6
229930003270 Vitamin B Natural products 0.000 claims abstract description 4
AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims abstract 2
AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract 2
235000019136 lipoic acid Nutrition 0.000 claims abstract 2
229960002663 thioctic acid Drugs 0.000 claims abstract 2
KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 17
239000007924 injection Substances 0.000 claims description 8
238000002347 injection Methods 0.000 claims description 8
239000000243 solution Substances 0.000 claims description 6
244000194101 Ginkgo biloba Species 0.000 claims description 5
235000008207 calcium folinate Nutrition 0.000 claims description 5
239000011687 calcium folinate Substances 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
239000002504 physiological saline solution Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 2
239000003826 tablet Substances 0.000 claims 6
229940088594 vitamin Drugs 0.000 claims 5
229930003231 vitamin Natural products 0.000 claims 5
235000013343 vitamin Nutrition 0.000 claims 5
239000011782 vitamin Substances 0.000 claims 5
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 4
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 3
150000003722 vitamin derivatives Chemical class 0.000 claims 3
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims 2
239000000843 powder Substances 0.000 claims 2
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 2
229960002477 riboflavin Drugs 0.000 claims 2
229940046001 vitamin b complex Drugs 0.000 claims 2
229940011671 vitamin b6 Drugs 0.000 claims 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
208000034693 Laceration Diseases 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 claims 1
239000011575 calcium Substances 0.000 claims 1
FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims 1
239000013078 crystal Substances 0.000 claims 1
229960002104 cyanocobalamin Drugs 0.000 claims 1
235000000639 cyanocobalamin Nutrition 0.000 claims 1
239000011666 cyanocobalamin Substances 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
229960003966 nicotinamide Drugs 0.000 claims 1
235000005152 nicotinamide Nutrition 0.000 claims 1
239000011570 nicotinamide Substances 0.000 claims 1
239000002674 ointment Substances 0.000 claims 1
235000008160 pyridoxine Nutrition 0.000 claims 1
239000011677 pyridoxine Substances 0.000 claims 1
229960004172 pyridoxine hydrochloride Drugs 0.000 claims 1
235000019171 pyridoxine hydrochloride Nutrition 0.000 claims 1
239000011764 pyridoxine hydrochloride Substances 0.000 claims 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 13
241000218628 Ginkgo Species 0.000 abstract description 7
230000008929 regeneration Effects 0.000 abstract description 2
238000011069 regeneration method Methods 0.000 abstract description 2
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
229930182478 glucoside Natural products 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
208000035475 disorder Diseases 0.000 description 14
239000008280 blood Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
208000024891 symptom Diseases 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
206010036105 Polyneuropathy Diseases 0.000 description 3
239000003708 ampul Substances 0.000 description 3
239000003978 infusion fluid Substances 0.000 description 3
230000007824 polyneuropathy Effects 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
239000009429 Ginkgo biloba extract Substances 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
229940068052 ginkgo biloba extract Drugs 0.000 description 2
235000020686 ginkgo biloba extract Nutrition 0.000 description 2
238000000034 method Methods 0.000 description 2
231100000957 no side effect Toxicity 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
210000000467 autonomic pathway Anatomy 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
201000002342 diabetic polyneuropathy Diseases 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000009689 neuronal regeneration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000012673 purified plant extract Substances 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Natural Medicines & Medicinal Plants (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Botany (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

JP1022466A 1988-01-28 1989-01-30 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤 Pending JPH0222229A (ja)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DE3802567.1		1988-01-28
DE3802567		1988-01-28
DE19883802895 DE3802895A1 (de)	1988-02-01	1988-02-01	Kombinationspraeparat zur behandlung von nervenzell- und nervenfasererkrankungen und verletzungen
DE3802895.6		1988-02-01
DE3813451		1988-04-21
DE3813451.9		1988-04-21

Publications (1)

Publication Number	Publication Date
JPH0222229A true JPH0222229A (ja)	1990-01-25

Family

ID=27197115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP1022466A Pending JPH0222229A (ja)	1988-01-28	1989-01-30	神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤

Country Status (6)

Country	Link
US (1)	US5118505A (2)
EP (1)	EP0326034B1 (2)
JP (1)	JPH0222229A (2)
DE (1)	DE58902094D1 (2)
ES (1)	ES2043897T3 (2)
GR (1)	GR3006061T3 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006129826A (ja) *	2004-11-09	2006-05-25	Sanei Gen Ffi Inc	α−リポ酸の劣化抑制方法およびα−リポ酸劣化抑制剤

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0557708A1 (de) *	1992-01-18	1993-09-01	Rabien, Margarethe	Arzneimittel die Liponsäure und Pantothensäure enthalten
DE59307753D1 (de) *	1992-03-11	1998-01-15	Asta Medica Ag	Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
US5569670A (en) *	1992-06-05	1996-10-29	Asta Medica Aktiengesellschaft	Combination medications containing alpha-lipoic acid and related
CA2133861C (en) *	1993-10-11	2004-03-30	Peter Koltringer	Preparation for the treatment of circulatory changes
DE4400269C2 (de) *	1994-01-10	1998-10-01	Asta Medica Ag	Tabletten mit Thioctsäure bestimmter Korngröße
AU2776495A (en) *	1994-06-20	1996-01-15	Kv Pharmaceutical Company	Vitamin/nutrient dosage regimentation
DE4439477C2 (de) *	1994-11-08	1999-10-21	Asta Medica Ag	Verwendung von R,S-(+/-)-alpha-Liponsäure, R-(+)-alpha-Liponäure, S-(-)-alpha-Liponsäure in reduzierter oder oxidierter Form oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung der diabetischen Mikroangiopathie
US5660835A (en) *	1995-02-24	1997-08-26	East Carolina University	Method of treating adenosine depletion
US20020032160A1 (en) *	1995-02-24	2002-03-14	Nyce Jonathan W.	Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
CN1122456C (zh)	1996-01-31	2003-10-01	南亚拉巴马医学科学基金会	含有天然的还原叶酸盐异构体的食品和维生素制品
US5948443A (en) *	1996-02-23	1999-09-07	Medical Doctor's Research Institute, Inc.	Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US5976568A (en) *	1997-02-21	1999-11-02	Medical Doctors' Research Institute, Inc.	Modular system of dietary supplement compositions for optimizing health benefits and methods
DE19807659A1 (de) *	1998-02-24	1999-08-26	Bender	Mittel zum Dekoagulieren von Blutplättchen
US6043259A (en) *	1998-07-09	2000-03-28	Medicure Inc.	Treatment of cardiovascular and related pathologies
CN1311665A (zh) *	1998-08-03	2001-09-05	新生制药公司	一种新的止痛、抗炎和创伤治疗剂
US6274170B1 (en)	1999-02-18	2001-08-14	Richard Heibel	Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same
US6339085B1 (en)	1999-03-08	2002-01-15	The University Of Manitoba	Therapeutics for cardiovascular and related diseases
US6489345B1 (en)	1999-07-13	2002-12-03	Medicure, Inc.	Treatment of diabetes and related pathologies
EP1872797A3 (en) *	1999-08-24	2008-04-02	Medicure International Inc.	Treatment of cardiovascular and related pathologies
DE19941217A1 (de) *	1999-08-30	2001-03-15	Asta Medica Ag	Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
US6573299B1 (en)	1999-09-20	2003-06-03	Advanced Medical Instruments	Method and compositions for treatment of the aging eye
US7442689B2 (en) *	2000-02-29	2008-10-28	Medicure International Inc.	Cardioprotective phosphonates and malonates
AU3718501A (en)	2000-02-29	2001-09-12	Medicure Int Inc	Cardioprotective phosphonates and malonates
NL1014636C2 (nl) *	2000-03-14	2002-07-16	Gales Anton	Vitaminepreparaat.
WO2001072309A2 (en)	2000-03-28	2001-10-04	Medicure International Inc.	Treatment of cerebrovascular disease
US20020009505A1 (en)	2000-06-01	2002-01-24	Yuanjin Tao	Compositions and methods for treating eye discomfort
WO2001091767A2 (en)	2000-06-01	2001-12-06	Theralife, Inc.	Compositions for enhancing therapeutic effects containing herbals and/or nutritional supplements and/or minerals and/or vitamins
US20040058015A1 (en) *	2000-06-01	2004-03-25	Yuanjin Tao	Compositions and methods for treating eye discomfort and eye disease
DE10027968A1 (de) *	2000-06-08	2001-12-13	Asta Medica Ag	Mittel zur Therapie von Demenzen
US6548519B1 (en)	2001-07-06	2003-04-15	Medicure International Inc.	Pyridoxine and pyridoxal analogues: novel uses
ATE364595T1 (de)	2000-07-07	2007-07-15	Medicure Int Inc	Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6897228B2 (en) *	2000-07-07	2005-05-24	Medicure International Inc.	Pyridoxine and pyridoxal analogues: new uses
US20020076470A1 (en) *	2000-10-31	2002-06-20	Colgate-Palmolive Company	Composition and method
US8669282B2 (en) *	2000-10-31	2014-03-11	Hill's Pet Nutrition, Inc.	Companion animal compositions including lipoic acid and methods of use thereof
US20040121988A1 (en) *	2001-03-28	2004-06-24	Medicure International Inc.	Treatment of cerebrovascular disease
AU2002303425A1 (en) *	2001-04-24	2002-11-05	Epigenesis Pharmaceuticals, Inc.	Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) *	2001-04-24	2002-11-05	East Carolina University	Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
ITGE20020026A1 (it) *	2002-03-25	2003-09-25	Segre Silvia Perella	Composto da impiegare nel trattamento scleroterapico,nell'insufficienza venosa e nelle alterazioni del microcircolo.
US7030154B2 (en)	2002-06-07	2006-04-18	Juvenon, Inc.	Stability of lipoic acid
EP1553954A4 (en) *	2002-06-17	2009-12-23	Epigenesis Pharmaceuticals Llc	DIHYDRATE DEHYDROEPIANDROSTERONE AND METHOD FOR THE TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE LUNG DISEASE, COMPOSITIONS THEREOF
US7405207B2 (en) *	2002-06-17	2008-07-29	Epigenesis Pharmaceuticals, Inc.	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US20040186077A1 (en) *	2003-03-17	2004-09-23	Medicure International Inc.	Novel heteroaryl phosphonates as cardioprotective agents
US20090285900A1 (en) *	2003-07-31	2009-11-19	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) *	2003-07-31	2009-11-19	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) *	2003-07-31	2005-02-17	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) *	2003-07-31	2005-02-24	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) *	2003-07-31	2009-11-05	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) *	2003-07-31	2005-05-26	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) *	2003-07-31	2005-05-12	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) *	2003-07-31	2005-04-21	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) *	2003-07-31	2009-12-03	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) *	2003-07-31	2009-10-22	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20060019929A1 (en) *	2004-07-07	2006-01-26	Albert Friesen	Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) *	2004-08-10	2007-03-15	Friesen Albert D	Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
WO2006050598A1 (en) *	2004-10-28	2006-05-18	Medicure International Inc.	Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) *	2004-10-28	2006-05-04	Medicure International Inc.	Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) *	2004-10-28	2008-12-02	Medicure International, Inc.	Aryl sulfonic pyridoxines as antiplatelet agents
WO2006058278A2 (en) *	2004-11-24	2006-06-01	Hill's Pet Nutrition, Inc.	Methods for improving liver clearance of xenobiotic substances in an animal
US20090176864A1 (en) *	2004-11-24	2009-07-09	Hill's Pet Nutrition, Inc.	Methods For Improving Hepatic and Immune Function In An Animal
DK1830883T3 (da)	2004-12-29	2013-11-25	Hills Pet Nutrition Inc	Fremgangsmåde til at hæmme en nedgang i indlæring og/eller hukommelse hos dyr
US8148325B2 (en) *	2004-12-30	2012-04-03	Hill's Pet Nutrition, Inc.	Methods for enhancing the quality of life of a senior animal
US8252742B2 (en) *	2004-12-30	2012-08-28	Hill's Pet Nutrition, Inc.	Methods for enhancing the quality of life of a senior animal
EP1906912B1 (en) *	2005-07-14	2012-08-15	Hill's Pet Nutrition, Inc.	Method for prolonging the life of animals
JP2009517411A (ja) *	2005-11-28	2009-04-30	メディキュアインターナショナルインコーポレーテッド	心血管及び関連病状の処置のための調剤
US7282225B1 (en)	2006-09-27	2007-10-16	Occular Technologies, Inc.	Composition and methods for improving retinal health
US20090054513A1 (en) *	2007-08-22	2009-02-26	Response Scientific, Inc.	Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) *	2007-08-22	2011-05-17	Response Scientific, Inc.	Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20100099751A1 (en) *	2008-10-21	2010-04-22	Al-Mulla Fahd	Method of treating diabetes-related vascular complications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3338995A1 (de) *	1983-10-27	1985-05-09	Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe	Bilobalid enthaltende arzneimittel
FR2518406A1 (fr) *	1981-12-22	1983-06-24	Prodipharm	Nouveau procede d'obtention de substances vaso-actives extraites de feuilles de ginkgo
EP0343694B1 (de) *	1984-03-07	1992-11-25	Roshdy Dr. Ismail	Mittel zur Behandlung und zum Schutz der Haut
US4753929A (en) *	1986-03-12	1988-06-28	Daicel Chemical Industries, Ltd.	Flavone glycoside

1989
- 1989-01-20 ES ES89100984T patent/ES2043897T3/es not_active Expired - Lifetime
- 1989-01-20 DE DE8989100984T patent/DE58902094D1/de not_active Expired - Lifetime
- 1989-01-20 EP EP89100984A patent/EP0326034B1/de not_active Expired - Lifetime
- 1989-01-25 US US07/301,424 patent/US5118505A/en not_active Expired - Fee Related
- 1989-01-30 JP JP1022466A patent/JPH0222229A/ja active Pending
1992
- 1992-10-22 GR GR920402386T patent/GR3006061T3/el unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006129826A (ja) *	2004-11-09	2006-05-25	Sanei Gen Ffi Inc	α−リポ酸の劣化抑制方法およびα−リポ酸劣化抑制剤

Also Published As

Publication number	Publication date
EP0326034A2 (de)	1989-08-02
US5118505A (en)	1992-06-02
ES2043897T3 (es)	1994-01-01
EP0326034A3 (en)	1990-11-07
GR3006061T3 (2)	1993-06-21
DE58902094D1 (de)	1992-10-01
EP0326034B1 (de)	1992-08-26

Publication	Publication Date	Title
JPH0222229A (ja)	1990-01-25	神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤
CN1211175A (zh)	1999-03-17	药物制剂以及一种人体的药物作用方法
US20210275580A1 (en)	2021-09-09	Iron carbohydrate complex for treatment of restless leg syndrome (rls)
JPH04295424A (ja)	1992-10-20	昏睡治療のためのアセチル−ｌ−カルニチンおよび医薬組成物
JPH04243825A (ja)	1992-08-31	色素沈着症治療剤
KR19980014498A (ko)	1998-05-25	부자-유황 복합제제
JP4786127B2 (ja)	2011-10-05	色素沈着改善治療薬
JPH10218775A (ja)	1998-08-18	筋萎縮性側索硬化症治療剤
CN100404039C (zh)	2008-07-23	一种红花药物组合物、其制备方法及其用途
US20040019107A1 (en)	2004-01-29	Homeopathic drug composition and methods of use thereof
KR102374820B1 (ko)	2022-03-16	프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물
JP3253878B2 (ja)	2002-02-04	鉄キレート化用製剤、その製剤の製法及び地中海貧血症の治療法
EP0402208B1 (fr)	1994-01-12	Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique
RU2152221C1 (ru)	2000-07-10	Средство, обладающее гепатопротекторным, холестерино- и сахарорегулирующим действием
EP2727595B1 (en)	2018-02-21	Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
DE19732323C2 (de)	1999-08-19	Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben
KR20230016006A (ko)	2023-01-31	포르피린증의 예방 또는 치료제
CN107737108B (zh)	2018-06-26	一种治疗心肌梗死后心室重塑的口服药物组合物
JPH04342528A (ja)	1992-11-30	アルコール代謝およびアセトアルデヒド代謝促進剤
CN105935443A (zh)	2016-09-14	一种治疗糖尿病性白内障的药物组合物
JP2941160B2 (ja)	1999-08-25	帯状疱疹による苦痛の緩和剤
RU2404976C1 (ru)	2010-11-27	Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения
DE2352618A1 (de)	1974-08-29	Arzneimittel zur behandlung des parkinsonismus
Heepe et al.	1987	Antianginal efficacy and tolerability of 50 mg sustained-release isosorbide 5-mononitrate in an open twelve-month observation study
JP2000229853A (ja)	2000-08-22	生理痛改善用組成物

JPH0222229A - 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (6)

Publications (1)

Family

ID=27197115

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (76)

Family Cites Families (4)

Cited By (1)

Also Published As

Similar Documents